Literature DB >> 30404743

2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.

Jason G Andrade1, Atul Verma2, L Brent Mitchell3, Ratika Parkash4, Kori Leblanc5, Clare Atzema6, Jeff S Healey7, Alan Bell8, John Cairns9, Stuart Connolly7, Jafna Cox4, Paul Dorian10, David Gladstone6, M Sean McMurtry11, Girish M Nair12, Louise Pilote13, Jean-Francois Sarrazin14, Mike Sharma7, Allan Skanes15, Mario Talajic16, Teresa Tsang9, Subodh Verma10, D George Wyse3, Stanley Nattel16, Laurent Macle17.   

Abstract

The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in atrial fibrillation (AF) management. This 2018 Focused Update addresses: (1) anticoagulation in the context of cardioversion of AF; (2) the management of antithrombotic therapy for patients with AF in the context of coronary artery disease; (3) investigation and management of subclinical AF; (4) the use of antidotes for the reversal of non-vitamin K antagonist oral anticoagulants; (5) acute pharmacological cardioversion of AF; (6) catheter ablation for AF, including patients with concomitant AF and heart failure; and (7) an integrated approach to the patient with AF and modifiable cardiovascular risk factors. The recommendations were developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) standards. Individual studies and literature were reviewed for quality and bias; the literature review process and evidence tables are included as Supplementary Material and are available on the CCS Web site. Details of the updated recommendations are presented, along with their background and rationale. This document is linked to an updated summary of all CCS AF guidelines recommendations, from 2010 to the present 2018 Focused Update, which is provided in the Supplementary Material.
Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30404743     DOI: 10.1016/j.cjca.2018.08.026

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  49 in total

1.  Catheter ablation did not reduce CV events and mortality more than drug therapy in symptomatic AF.

Authors:  Gaetano Santulli
Journal:  Ann Intern Med       Date:  2019-07-16       Impact factor: 25.391

2.  Computational models of the atrial fibrillation substrate: can they explain post-ablation recurrences and help to prevent them.

Authors:  Stanley Nattel
Journal:  Cardiovasc Res       Date:  2019-10-01       Impact factor: 10.787

Review 3.  Is alteration in single drug anticoagulant/antiplatelet regimen necessary in patients who need minor oral surgery? A systematic review with meta-analysis.

Authors:  Thayanne Barbosa Brasil Calcia; Harry Juan Rivera Oballe; Alice Maria de Oliveira Silva; Stephanie Anagnostopoulos Friedrich; Francisco Wilker Mustafa Gomes Muniz
Journal:  Clin Oral Investig       Date:  2021-03-23       Impact factor: 3.573

4.  Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.

Authors:  Madeleine Durand; Mireille E Schnitzer; Menglan Pang; Greg Carney; Sherif Eltonsy; Kristian B Filion; Anat Fisher; Min Jun; I Fan Kuo; Christel Renoux; J Michael Paterson; Jacqueline Quail; Alexis Matteau
Journal:  CMAJ Open       Date:  2020-12-18

5.  Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.

Authors:  William F McIntyre; Jeff S Healey; Akash K Bhatnagar; Patrick Wang; Jacob A Gordon; Adrian Baranchuk; Bishoy Deif; Richard P Whitlock; Émilie P Belley-Côté
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

6.  New electrocardiographic score for the prediction of atrial fibrillation: The MVP ECG risk score (morphology-voltage-P-wave duration).

Authors:  Bryce Alexander; Julia Milden; Bachar Hazim; Sohaib Haseeb; Antoni Bayes-Genis; Roberto Elosua; Manuel Martínez-Sellés; Cynthia Yeung; Wilma Hopman; Antoni Bayes de Luna; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-06-11       Impact factor: 1.468

7.  Bleeding in patients with atrial fibrillation treated with combined antiplatelet and anticoagulant therapy: time to turn the corner.

Authors:  Ke Xu; Noel C Chan
Journal:  Ann Transl Med       Date:  2019-09

8.  Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study.

Authors:  Eric K C Wong; Christina Belza; David M J Naimark; Sharon E Straus; Harindra C Wijeysundera
Journal:  CMAJ Open       Date:  2020-11-06

9.  Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.

Authors:  Elvira Grandone; Filippo Aucella; Doris Barcellona; Giuliano Brunori; Giacomo Forneris; Paolo Gresele; Marco Marietta; Daniela Poli; Sophie Testa; Armando Tripodi; Simonetta C Genovesi
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

10.  Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure.

Authors:  Michelle Samuel; Michal Abrahamowicz; Jacqueline Joza; Marie-Eve Beauchamp; Vidal Essebag; Louise Pilote
Journal:  Europace       Date:  2020-05-01       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.